SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-006720
Filing Date
2021-01-12
Accepted
2021-01-12 06:15:02
Documents
14
Period of Report
2021-01-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d17484d8k.htm   iXBRL 8-K 39537
2 EX-2.1 d17484dex21.htm EX-2.1 500683
3 EX-99.1 d17484dex991.htm EX-99.1 13035
  Complete submission text file 0001193125-21-006720.txt   809723

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA amrx-20210112.xsd EX-101.SCH 3063
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE amrx-20210112_lab.xml EX-101.LAB 17373
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amrx-20210112_pre.xml EX-101.PRE 10948
7 EXTRACTED XBRL INSTANCE DOCUMENT d17484d8k_htm.xml XML 3245
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 21522362
SIC: 2834 Pharmaceutical Preparations